These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 4397165)

  • 1. [Abnormal movements observed during treatment of Parkinson's disease with L-dopa].
    Sigwald J; Raymondeaud C
    Rev Neurol (Paris); 1970 Feb; 122(2):103-12. PubMed ID: 4397165
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance and pathogenesis of abnormal movements during L-dopa therapy of Parkinson's disease.
    Barbeau A
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534982
    [No Abstract]   [Full Text] [Related]  

  • 3. L-dopa induced dyskinesias in 152 patients with Parkinson's disease.
    Mones RJ; Elizan TS; Siegel G
    Trans Am Neurol Assoc; 1970; 95():286-7. PubMed ID: 5514393
    [No Abstract]   [Full Text] [Related]  

  • 4. An analysis of L-dopa-induced dyskinesias in 152 cases of Parkinson's disease.
    Mones RJ; Elizan TS; Siegel GJ
    Neurology; 1970 Apr; 20(4):405-6. PubMed ID: 5535050
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa therapy in Parkinson's disease.
    Lipman IJ
    Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J; Klaiber R; Perret E; Ziegler WH
    Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 8. L-Dopa therapy of Parkinson's disease. (A review of the preliminary experience at West Virginia University).
    Gutmann L; Martin JD; Gutrecht JA
    W V Med J; 1970 Apr; 66(4):109-11. PubMed ID: 5264660
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G; Castaigne P; Lhermitte F; Beck H; Guillard A; Marteau R; Pepin B; Rondot P; Raphy B
    Rev Neurol (Paris); 1970 Feb; 122(2):89-102. PubMed ID: 4931719
    [No Abstract]   [Full Text] [Related]  

  • 10. [Collateral effects of therapy with L-dopa in Parkinson's disease].
    Gomirato G; Perfetti CC; Ecari U
    Sist Nerv; 1970; 22(2):67-73. PubMed ID: 5504559
    [No Abstract]   [Full Text] [Related]  

  • 11. [Problems and therapy of L-DOPA-induced dyskinesias].
    Völler GW; Deze J; Gundlach U; Muschard F
    Nervenarzt; 1972 Nov; 43(11):584-6. PubMed ID: 4564994
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical study of L-dopa in Parkinson's disease].
    Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
    Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
    [No Abstract]   [Full Text] [Related]  

  • 13. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
    Buscaino GA; Campanella G
    Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561
    [No Abstract]   [Full Text] [Related]  

  • 14. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
    Lhermitte F; Rosa A; Comoy E; Bohuon C
    Rev Neurol (Paris); 1973 Dec; 129(6):313-24. PubMed ID: 4794176
    [No Abstract]   [Full Text] [Related]  

  • 15. Side effects of L-dopa treatment.
    Greenburg J
    Pa Med; 1971 Apr; 74(4):55-6. PubMed ID: 5147645
    [No Abstract]   [Full Text] [Related]  

  • 16. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 17. Failures of L-dopa.
    Paulson GW
    Ohio State Med J; 1973 Dec; 69(12):896-8. PubMed ID: 4769406
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 19. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract]   [Full Text] [Related]  

  • 20. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.